Live Breaking News & Updates on Formycon Ag Via Public Receives Positive Scientific Advice From Paul Ehrlich Institute For The Covid 19 Drug Fyb207 And Assures Gmp Manufacturing Capacities

02/24/2021 | Press release | Distributed by Public on 02/24/2021 00:09
Formycon receives positive Scientific Advice from Paul-Ehrlich-Institute for the COVID-19 Drug FYB207 and assures GMP Manufacturing Capacities
Process development, preclinical as well as concepts for clinical phase I and phase II aligned
Accelerated review of applications for clinical trials
Manufacturing capacities for FYB207 assured at experienced German GMP manufacturer
Scientific Advice Meeting with the U.S. Food and Drug Administration (FDA) in preparation
Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) has received the consent from the Paul-Ehrlich-Institute (PEI) regarding the proposed development concept for its innovative SARS-CoV-2 blocker FYB207. As result of the Scientific Advice, the Federal Institute for Vaccines and Biomedicines supports Formycon s approach in the further development of FYB207. In particular, analytics, process development, manufacturing (so-called ....

Carsten Brock Meyer , Johannes Buchner , Ulrike Protzer , Stefan Glombitza , Technical University Of Munich , Institute For Vaccines , Drug Administration , Scientific Advice , Federal Institute , Scientific Advice Meeting , Technical University , Formycon Ag Via Public Receives Positive Scientific Advice From Paul Ehrlich Institute For The Covid 19 Drug Fyb207 And Assures Gmp Manufacturing Capacities , ஜோஹன்னஸ் புகினேர் , தொழில்நுட்ப பல்கலைக்கழகம் ஆஃப் முனிச் , நிறுவனம் க்கு தடுப்பு மருந்துகள் , கூட்டாட்சியின் நிறுவனம் , தொழில்நுட்ப பல்கலைக்கழகம் ,